Progesterone antagonists and progesterone receptor modulators: an overview

Area of Science:

• Endocrinology
• Pharmacology
• Reproductive Medicine

Background:

• Mifepristone, an antiprogestin, and related compounds function as progesterone antagonists (PAs) or progesterone receptor modulators (PRMs).
• PAs and PRMs exhibit mixed agonist-antagonist activities, with significant therapeutic potential in women's healthcare.

Purpose of the Study:

• To review the diverse therapeutic applications of PAs and PRMs in female health and other medical conditions.
• To highlight the mechanisms and potential uses of these compounds in reproductive endocrinology and beyond.

Main Methods:

• Literature review of synthesized PAs and PRMs.
• Analysis of their pharmacological activities and clinical applications.

Main Results:

• Mifepristone, a PA, is effective in pregnancy termination and managing menses delay.
• PAs and PRMs demonstrate antiproliferative effects on the endometrium, aiding in endometriosis and myoma treatment without hypoestrogenism.
• These compounds show contraceptive potential by inhibiting follicular development, blocking LH surge, or retarding endometrial maturation.
• PAs and PRMs are also potent antiglucocorticoid agents, useful for Cushing's syndrome and other conditions requiring ACTH-cortisol axis suppression.

Conclusions:

• PAs and PRMs represent a versatile class of drugs with broad applications in gynecology, contraception, and endocrinology.
• Their ability to modulate progesterone receptor activity offers targeted therapeutic strategies for various conditions.